English
Make accurate cancer screening available to more people with a completely non-invasive, no-contact testing and monitoring option.
miR’s industry-leading level of accuracy and accessibility in diagnosing, classifying, and monitoring prostate cancer can meaningfully alleviate the economic and human burden of one of the world’s most prevalent and deadly diseases.
Accuracy with miR proprietary
diagnosis solution
Our disease management platform uses precise biologic information interrogation techniques to categorize patients into one of four groups: no molecular evidence of cancer, low-risk, intermediate-risk, or high-risk.
This gives physicians the ability to clearly determine which patients need treatment and which can be safely and non-invasively monitored helps avoid harmful and costly overtreatment.
Our highly accurate, easy-to-administer urine tests are powered by an algorithm-based disease management platform to help physicians diagnose and monitor patients across the continuum of cancer care for optimal case management and prioritization.
miR is the only prostate cancer test that provides an accurate measure of molecular malignancy to answer the most critical cancer questions. When it comes to cancer, we provide answers, not more questions.
Outperform today’s standard of care and decrease the invasiveness for your patients. Our results will transform the standard of urologic oncology care with highly accurate, easily administered, and cost-effective end-to-end cancer management tools that reduce poor outcomes and eliminate waste.
The miR disease management platform delivers clarity and peace of mind to all involved in prostate cancer care from diagnosis through disease management:
Identify the patients in greatest need quickly and accurately so you can deliver critical cancer care without delay. Confidently monitor low-risk patients efficiently and non-invasively.
Experience a non-invasive, pain-free, accessible prostate cancer test that delivers clear, accurate results to you and your doctor quickly from a single urine specimen.
Keep your employees and their families healthy and reduce excessive urologic cancer screening and treatment costs with a straightforward, validated, and highly accessible urine test.
One urine sample is all that’s required to accurately diagnose and classify prostate cancer with 95% specificity, avoiding the standard invasive and inaccurate screening procedures. Our breakthrough Disease Management Platform™ enables timely and accurate progression monitoring and care planning at all stages of the disease.
In addition to being extremely invasive and potentially leading to impotence, incontinence, infection and overtreatment, the PSA test and biopsy combination has just a 44% sensitivity level—making it highly inaccurate and necessary to repeat often.
Although elevated PSA levels can be an indicator of the presence of prostate cancer, many other factors not related to cancer can return an elevated PSA test.
Medical literature shows that 7 out of 10 prostate biopsies are deemed unnecessary.
The positive predictive value of elevated PSA for prostate cancer is less than 30%.
70% of patients undergoing prostate biopsies receive a negative result.
Avoid the inaccurate, often unnecessary PSA test–rectal exam–biopsy cycle and get real answers fast. miR provides industry-low false-positive and false-negative rates for maximum confidence in clinical pathways.
miR delivers accurate diagnosis and classification results using highly accurate molecular RNA interrogation and sophisticated algorithms based on hundreds of biomarkers.
Get actionable, accurate disease information to appropriately guide the course of care with just one urine test.
